1. Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity.
- Author
-
JU-YOUNG KIM, JI-HWAN HWANG, MI-RAN CHA, MI-YOUNG YOON, EUN-SOON SON, AKIHIRO TOMIDA, BOSUNG KO, SI-WHAN SONG, KAZUO SHIN-YA, YONG-IL HWANG, and HAE-RYONG PARK
- Subjects
CANCER cells ,TUMORS ,HYPOXEMIA ,GENES ,PHOSPHORYLATION ,ANTINEOPLASTIC agents - Abstract
Cancer cells in poorly vascularized solid tumors are constantly or intermittently exposed to stressful microenvironments, including glucose deprivation, hypoxia, and other forms of nutrient starvation. These tumor-specific conditions, especially glucose deprivation, activate a signaling pathway called the unfolded protein response (UPR), which enhances cell survival by induction of the stress proteins. We have established a screening method to discover anticancer agents that could preferentially inhibit tumor cell viability under glucose-deprived conditions. Here we identify arctigenin (ARC-G) as an active compound that shows selective cytotoxicity and inhibits the UPR during glucose deprivation. Indeed, ARC-G blocked expression of UPR target genes such as phosphorylated-PERK, ATF4, CHOP, and GRP78, which was accompanied by enhanced phosphorylation of eIF2α during glucose deprivation. The UPR inhibition led to apoptosis involving a mitochondrial pathway by activation of caspase-9 and -3. Furthermore, ARC-G suppressed tumor growth of colon cancer HT-29 xenografts. Our results demonstrate that ARC-G can be served as a novel type of antitumor agent targeting the UPR in glucose-deprived solid tumors. J. Cell. Physiol. 224:33–40, 2010 © 2010 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF